How we do it

Everyone at GSK focuses on three priorities: Innovation, Performance, Trust


We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.


Research and Development investment in 2018


new medicines in development at Q2 2019


oncology assets in our pipeline at Q2 2019, which has more than doubled from 8 in the last 12 months




We aim to achieve industry-leading growth by investing effectively in our business, developing our people and delivering flawlessly.


total turnover in 2018


adjusted operating profit in 2018


free cash flow in 2018


dividends paid in 2018



We are a responsible company and commit to use our science and technology to address health needs, make our products affordable and available and to be a modern employer. 


employee engagement score on our latest employee survey


donated in 2018 to community health programmes


in Access to Medicines Index since the assessment began in 2008